Established in 2011, SnackSafely.com provides straightforward, actionable information to help improve the lives of the estimated 32 million people in the US suffering with food allergies.

We strive to eliminate anaphylaxis by leveraging our on-line properties to educate, advocate, and connect the allergic community with products and services that help toward achieving this goal.

Our blog covers topics of interest to the food allergy community including news reports; ongoing research, clinical studies, trials and progress toward treatment and cure; general advocacy; and advice regarding food safety and school policies.

Please see our Terms of Service and Privacy Policy.

Emerging Therapy

Potential Breakthrough for Celiac Disease: Teva Antibody Significantly Reduces Gluten-Induced Gut Damage

Rare Antibodies Could Lead to First Targeted Treatment for Alpha-Gal Syndrome

Another Potential Food Allergy Treatment is Snapped Up by Big Pharma

Microneedle Stamp for Peanut Allergy Moves Through First Human Trial

Could Metformin—a Cheap, Common Diabetes Medication—Be the Next Food Allergy Treatment?

Intra-Nasal Epinephrine Takes Step Forward After Three Positive Pre-Clinical Studies

FDA Approves Dupixent® as First Biologic for Treatment of Children Aged...

Allerdent Enables Patients to Maintain Seasonal Allergy Immunotherapy During COVID-19 Pandemic

Oral Immunotherapy: What You Should Know, and What’s New (Webinar)

Pending Litigation Shows Food Allergy Treatments in Development are Sometimes Overhyped

BlueWillow Completes Preclinical Studies of Intranasal Peanut Allergy Vaccine

FDA Has Questions About Viaskin Peanut Efficacy, Delays Meeting with DBV...

ARS to Present Data from Intranasal Epinephrine (ARS-1) Studies at AAAAI...

FDA Advisory Committee Meeting to Review Viaskin Peanut for the Treatment...

Alladapt Immunotherapeutics Secures $60 Million in Series C Financing for Development...

Follow Us

Your School On Our Map

Put Your School on the Map